[The prophylactic effect of thymosin alpha 1 on the acute exacerbation of chronic obstructive pulmonary disease].

Zheng BX, Cheng DY, Xu G, Fan LL, Yang Y, Yang W

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition1 Jul 2008Cited by 4 (Europe PMC)

PMID18798500PepBankPUB-18798500

Publisher pageAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with chronic obstructive pulmonary disease, the number of patients with acute exacerbation was significantly lower with thymosin alpha‑1 than in the control group.
In plain wordsIn people with COPD, fewer patients had flare-ups with thymosin alpha‑1 than in the control group.
Peptide
Thymosin alpha-1
Outcome
DecreaseNumber of patients with acute exacerbation of COPD
Study
n = 80
Comparator
Control group
Outcome group
Respiratory function · Respiratory
Studied dose
1.6 mg · hypodermic injection · 10 injections, every other dayAs given in this study (human).
Source sentences
Summary
In the treatment group, the number and days of patients with acute exacerbation were significantly lower in comparison with those of the control group.
2 context sentences(design, population, supporting numbers)
Summary · context
Eighty patients with chronic obstructive pulmonary disease were divided into two groups.
Summary · context
In the treatment group, 42 patients received thymosin alpha 1 1.6 mg hypodermic injection, quague die alterna, for 10 times.
Report a problemFND-1879850001
02HumanRandomized controlled trialEfficacy outcome
In patients with chronic obstructive pulmonary disease, the days with acute exacerbation were significantly lower with thymosin alpha‑1 than in the control group.
In plain wordsIn people with COPD, flare-up days were fewer with thymosin alpha‑1 than in the control group.
Peptide
Thymosin alpha-1
Outcome
DecreaseDays of acute exacerbation of COPD
Study
n = 80
Comparator
Control group
Outcome group
Respiratory function · Respiratory
Studied dose
1.6 mg · hypodermic injection · 10 injections, every other dayAs given in this study (human).
Source sentences
Summary
In the treatment group, the number and days of patients with acute exacerbation were significantly lower in comparison with those of the control group.
2 context sentences(design, population, supporting numbers)
Summary · context
Eighty patients with chronic obstructive pulmonary disease were divided into two groups.
Summary · context
In the treatment group, 42 patients received thymosin alpha 1 1.6 mg hypodermic injection, quague die alterna, for 10 times.
Report a problemFND-1879850002
03HumanRandomized controlled trialEfficacy outcome
In patients with chronic obstructive pulmonary disease, blood CD4 levels increased significantly after thymosin alpha‑1.
In plain wordsIn people with COPD, blood CD4 cell levels rose after thymosin alpha‑1.
Peptide
Thymosin alpha-1
Outcome
IncreaseBlood CD4 level
Study
n = 42
Outcome group
Immune response · Immune and inflammation
Studied dose
1.6 mg · hypodermic injection · 10 injections, every other dayAs given in this study (human).
Source sentences
Summary
After treatment of thymosin alpha 1, blood CD4 and CD4/CD8 levels were significantly increased.
2 context sentences(design, population, supporting numbers)
Summary · context
Eighty patients with chronic obstructive pulmonary disease were divided into two groups.
Summary · context
In the treatment group, 42 patients received thymosin alpha 1 1.6 mg hypodermic injection, quague die alterna, for 10 times.
Report a problemFND-1879850003
04HumanRandomized controlled trialEfficacy outcome
In patients with chronic obstructive pulmonary disease, the blood CD4/CD8 ratio increased significantly after thymosin alpha‑1.
In plain wordsIn people with COPD, the blood CD4/CD8 cell ratio rose after thymosin alpha‑1.
Peptide
Thymosin alpha-1
Outcome
IncreaseBlood CD4/CD8 ratio
Study
n = 42
Outcome group
Immune response · Immune and inflammation
Studied dose
1.6 mg · hypodermic injection · 10 injections, every other dayAs given in this study (human).
Source sentences
Summary
After treatment of thymosin alpha 1, blood CD4 and CD4/CD8 levels were significantly increased.
2 context sentences(design, population, supporting numbers)
Summary · context
Eighty patients with chronic obstructive pulmonary disease were divided into two groups.
Summary · context
In the treatment group, 42 patients received thymosin alpha 1 1.6 mg hypodermic injection, quague die alterna, for 10 times.
Report a problemFND-1879850004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT03659578

Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer

Sun Yat-sen Universityn = 699 Aug 2018 to 30 Sept 2021

Non-small Cell Lung Cancer

Trial page ClinicalTrials.govUpdated 3 Jan 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 17:28 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.